Medscheme released updated MEDICINE EXCLUSION LIST APRIL 2023

By HEOR Staff Writer

April 10, 2023

Some items listed as REQUIRING PRE-AUTHORISATION:

  • Forxiga (Dapagliflozin)
  • Byetta (Exenatide)
  • Janumet (Metformin/Sitagliptin)
  • Onglyza (Saxagliptin)
  • Januvia (Sitagliptin)
  • Galvus (Vildagliptin) + including Metformin combinations
  • Liptruzet (Atorvastatin/Ezetimibe)
  • Ezetrol (Ezetimibe)
  • Inegy(Ezetimibe/Simvastatin)

Details regarding the EXCLUDED ITEMS:

  • Trulicity (Dulaglutide)
  • Jardiance (Empagliflozin)
  • Xultophy (Insulin Degludec and Liraglutide)
  • Soliqua (Insulin Glargine and Lixisenatide)
  • Victoza (Liraglutide)
  • Synjardy (Metformin and Empagliflozin)
  • Ozempic (Semaglutide)
Reference url

Recent Posts

Social Media Policy Action: Protecting Youth from Cognitive Risks

By João L. Carapinha

October 16, 2025

A recent editorial published in JAMA emphasizes the urgent need for social media policy action due to the developmental impacts of social media on youth. The article discusses a pivotal study by Nagata et al., which examined a large cohort of adolescents. This study revealed that increas...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine and Drug Discourse

By João L. Carapinha

October 7, 2025

The BMJ article “Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists” argues that political and ideological actors, notably aligned with the MAGA movement, are promoting health misinformation about autism, vaccines, and paracetamol. They amplify preliminary, misinterprete...
The Market Dynamics of Track One Patent Strategy in Pharmaceuticals

By Rene Pretorius

September 26, 2025

In the interconnected landscape of pharmaceutical regulation and innovation, the Track One patent strategy in pharmaceuticals serves as an important component that influences the timing of mar...